Artificial intelligence (AI) software developer Cleerly has raised additional funds, closing its most recent series C funding round after securing a total of $223 million.
Cleerly reported that it raised additional funds on top of the $192 million it reported raising last week. The oversubscribed funding round was led by funds and accounts advised by T. Rowe Price Associates, T. Rowe Price Investment Management, and Fidelity Management and Research, according to Cleerly.
Other participants included Sands Capital, Piper Sandler's Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis, and Pura Vida Investments, along with existing investors such as Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, and DigiTx Partners.
Cleerly is developing AI-based software designed to assist physicians in identifying, characterizing, and quantifying atherosclerosis on coronary CT angiography exams. The firm said it would use the new funds to extend its commercial reach and invest in additional large-scale outcomes research.
More than a dozen multicenter clinical trials are currently underway, including an international registry that will enroll more than 100,000 patients over the next decade, according to Cleerly.
The company has now raised a total of $279 million.
